Pharmacogenomics in cancer therapy: is host genome variability important?

Published

Journal Article (Review)

Pharmacogenomics aims to elucidate the genomic determinants of drug disposition and effect. Because cancer chemotherapy is relatively nonspecific and has narrow therapeutic indices, there is great potential for pharmacogenomics to improve treatment outcomes by either reducing toxicity or increasing efficacy. The diversity of therapeutic targets for anticancer drugs and the intensity of clinical pharmacology research in oncology have provided many examples of clinically relevant pharmacogenomic applications. Important elements that are discussed in this article include the association of genetic variability in the metabolism, intracellular transport and targets of anticancer drugs. In addition, we summarize where the field stands currently, and how information from the host and tumor might be integrated into decision making.

Full Text

Duke Authors

Cited Authors

  • Petros, WP; Evans, WE

Published Date

  • September 2004

Published In

Volume / Issue

  • 25 / 9

Start / End Page

  • 457 - 464

PubMed ID

  • 15559247

Pubmed Central ID

  • 15559247

International Standard Serial Number (ISSN)

  • 0165-6147

Digital Object Identifier (DOI)

  • 10.1016/j.tips.2004.07.007

Language

  • eng

Conference Location

  • England